BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 15943950)

  • 1. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention.
    Burns L; Randall D; Hall WD; Law M; Butler T; Bell J; Degenhardt L
    Addiction; 2009 Aug; 104(8):1363-72. PubMed ID: 19549053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of costs and utilization among buprenorphine and methadone patients.
    Barnett PG
    Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
    Bell J; Trinh L; Butler B; Randall D; Rubin G
    Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
    Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
    J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services.
    Whitley SD; Kunins HV; Arnsten JH; Gourevitch MN
    J Subst Abuse Treat; 2007 Jul; 33(1):85-90. PubMed ID: 17588493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
    Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
    Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department.
    Berg ML; Idrees U; Ding R; Nesbit SA; Liang HK; McCarthy ML
    Drug Alcohol Depend; 2007 Jan; 86(2-3):239-44. PubMed ID: 16930865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of patients with moderately severe methadone dependence onto buprenorphine.
    Glasper A; Reed LJ; de Wet CJ; Gossop M; Bearn J
    Addict Biol; 2005 Jun; 10(2):149-55. PubMed ID: 16191667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ
    J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
    Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.